40
Participants
Start Date
March 6, 2017
Primary Completion Date
February 22, 2022
Study Completion Date
February 22, 2022
Satoreotide tetraxetan
Satoreotide tetraxetan administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
Amino acid solution
"Given as an auxiliary product the day of the IMP infusion for safety reasons to protect the renal function.~Centres can use their established amino acid infusion or Ipsen amino acid solution (auxiliary medical product OPS301)"
Antiemetic
To counteract the known side effects of the amino acid infusion, such as nausea, dexamethasone (antiemetic) and as-required ondansetron will be administered 15 to 30 minutes before the start of the amino acid infusion (unless there are contraindications for these drugs).
University Hospital Vienna, Department of Nuclear Medicine, Vienna
Peter MacCallum Cancer Centre, Molecular Imaging and Targeted Therapeutics Laboratory, East Melbourne
University Hospital Basel, Department of Nuclear Medicine, Basel
Ramsay Hollywood Private Hospital, Department of Nuclear Medicine, Perth
University Hospital Aarhus, Department of Hepatology and Gastroenterology, Aarhus
CHU de Nantes, Hotel Dieu, Service de Medecine Nucleaire, Nantes
MD Anderson Cancer Center, Department of Nuclear Medicine, Houston
CHU de Quebec - Universite Laval Research Center, Department of Radiology and Nuclear Medicine, Québec
Royal Free Hospital, Department of Nuclear Medicine, London
Lead Sponsor
Ipsen
INDUSTRY